Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Tempest_Therapeutics
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:CEO |
Julia Owens
|
| gptkbp:focus |
rare diseases
endocrine diseases |
| gptkbp:foundedYear |
2012
|
| gptkbp:founder |
Julia Owens
|
| gptkbp:headquartersLocation |
gptkb:Ann_Arbor,_Michigan,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Millendo Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
livoletide
nevanimibe |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:MLND
|
| gptkbp:website |
https://www.millendo.com/
|
| gptkbp:bfsParent |
gptkb:OvaScience
|
| gptkbp:bfsLayer |
6
|